Effects of anti-platelet individual treatment guided by CYP2C19 polymorphism

doi:10.12092/j.issn.1009-2501.2018.12.008

Abstract

Abstract:

AIM: To investigate the genetic polymorphism of CYP2C19 among patients requiring percutaneous coronary intervention（PCI）, and to determine the anticoagulation therapy according to genotypes so as to observe its clinical efficacy. METHODS: CYP2C19 variants were detected by PCR-RFLP method in patients requiring PCI. The extensive metabolism（EM）group was treated with clopidogrel with loading dose of 300 mg at the first time and 75 mg/d for 12 months.While the intermediate metabolism (IM) group was treated with clopidogrel with loading dose of 300 mg at the first time and 150 mg/d for 12 months.The poor metabolism (PM) group was treated with ticagrelor with loading dose of 180 mg at the first time and 90 mg,bid for 12 months.All three groups were given Aspirin of 100 mg/d. During the follow-up of 12 months,the incidence rates of major adverse cardiac events （MACE） in the three groups were observed and compared. RESULTS: Five genotypes of CYP2C19 were found in these subjects,and that the frequency of EM was 37.6%,IM 55.6% and PM 6.8%.No significant difference related to the incidence rates of major adverse cardiac events in the three groups during the follow-up of 12 months was observed. CONCLUSION: CYP2C19 genotype can instruct the medication of anticoagulation therapy; patients with fast metabolism can receive regular dose of clopidogrel, while patients with mutation should consider larger dose of clopidogrel or other anticoagulation drugs.

Key words: CYP2C19, genotype polymorphism, PCI, individualized therapy

CLC Number:

ZHOU Jianhua, LIU Kelan, WU Ganbin. Effects of anti-platelet individual treatment guided by CYP2C19 polymorphism[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(12): 1364-1367.

References

［1］孙雪梅. 硫酸氢氯吡格雷联合阿司匹林对经皮冠状动脉介入术的术后心肌保护作用研究［J］. 中国临床药理学杂志，2016，32(13)：1158-1161.
［2］蒋长荣. 冠心病患者经皮冠状动脉介入治疗术后氯吡格雷抵抗的影响因素研究［J］. 实用心脑肺血管病杂志，2017, 25(2)：26-30.
［3］陈珲，蔡泓敏，冯端浩，等. CYP2C9和CYP2C19基因多态性对药物代谢的影响及个体化用药研究进展［J］. 中国药物应用与监测, 2014, 11(4): 240-243,244.
［4］李好好，石晶，王回，等. 氯吡格雷抵抗与基因多态性的相关性研究进展［J］. 中华老年心脑血管病杂志, 2017，19(11): 1216-1219.
［5］冯亚娟, 周建华, 刘科兰, 等. 丙戊酸代谢相关CYP2C19基因多态性在癫痫患儿体内的分布及治疗个体化研究［J］. 中国实用神经疾病杂志, 2015, 18(5): 49-52.
［6］Sabatine MS, Cannon CP, Gibson CM, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocarction with ST-segment elevation ［J］. N Engl J Med, 2005, 352(12): 1179-1189.
［7］Guirgis M, Thompson P, Jansen S. Review of aspirin and clopidogrel resistance in peripheral arterial disease ［J］. J Vasc Surg, 2017, 5214 (17): 31785-31788.
［8］胡晶晶，陈小云，周伟，等. CYP2C19基因多态性对急性冠状动脉综合征合并糖尿病患者PCI预后的影响［J］. 疑难病杂志, 2016, 15(1): 18-21.
［9］朱宏旭，宋丽萍，耿学峰，等. 氯吡格雷药物代谢基因CYP2C19多态性对冠心病PCI术后患者支架再狭窄的影响［J］. 中国医药导刊，2017，19(12): 1344-1347.
［10］王晋星，刘倩，严进红，等. CYP2C19基因多态性对氯吡格雷低反应影响的系统评价［J］.中国医院用药评价与分析，2017，17(6): 806-809,813.
［11］Zhou HH.Genetic polymorphism of CYP2C19 in Chinese ethnic populations［J］.Int Con Ser，2002，1244:51-61.
［12］徐俊丽，易福凌，刘永国，等. CYP2C19基因多态性与幽门螺杆菌阳性老年胃癌患者的关系研究［J］. 疑难病杂志, 2015, 14(4): 356-358, 362.
［13］张银妆，莫珍珍，戴玮，等. 氯吡格雷对基于CYP2C19分型的健康人血浆eNOS和NO水平影响的研究［J］. 中国临床药理学与治疗学, 2016, 21(3): 298-305.
［14］黄文莺，刘亦伟，王长连，等. 福建籍汉族冠心病患者CYP2C19基因多态性［J］. 中国老年学杂志，2015, 35(16)：4504-4507.
［15］杨雅薇，李攀，陈韬，等. CYP2C19基因型检测对的指导作用PCI术后氯吡格雷应用的指导作用［J］. 应用国际心血管杂志，2015, 42(1)：13-14.
［16］方莉，刘瑶，张永香，等. CYP2C19基因多态性与氯吡格雷个体化用药的相关性研究［J］.川北医学院学报，2018，33(1)：70-73.
［17］汤毅，陈魁，党瑜华，等. 高维持量氯吡格雷和替格瑞洛临床疗效对比研究［J］. 中国实用医刊，2015, 42(5)：43-45.
［18］杨禹娟，张炜，李喆，等. CYP2C19基因多态性对PCI术后抗血小板治疗的指导作用［J］.心血管康复医学杂志, 2017, 26(5): 493-496.
［19］刘娜，仵文英，张抗怀，等. 基于CYP2C19基因多态性的氯吡格雷抵抗早期筛查及精准治疗［J］. 医药导报，2017, 36(5)：524-528.
［20］黄群, 刘奇良, 徐敏敏. CYP2C19药物基因多态性对冠心病患者抗血小板药物个体化治疗的指导［J］. 血栓与止血学，2017，23(6)：918-920.

[1]	QIAN Jin, WANG Fengyan. Influence factors of serum NT-proBNP level in elderly patients with acute myocardial infarction after PCI and its influence on short-term prognosis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 658-665.
[2]	CHEN Manxin, ZHANG Bingyu, DAI Min. Clinical efficacy of intracoronally targeted recombinant human urokinase combined with percutaneous coronary intervention (PCI) in acute myocardial infarction (AMI) with high thrombus burden [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 544-549.
[3]	LI Mengxue, HE Jie, YU Xiaxia, HU Linlin, SHAO Hua. Research progress in population pharmacokinetics of rituximab [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 468-474.
[4]	XIA Chunyong, ZHANG Zuowen, HE Xiaoyan, LIU Jie, LI Xiaoya, CHANG Qiuhong, QIN Lijuan, CAO Zhenming, DING Ling. Correlation between CYP2C19 gene polymorphism and individualized medication in patients with ischemic stroke [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(3): 318-323.
[5]	XU Honglei, XU Bingxin, ZU Qing, ZHAO Yan, GAO Pengfei, YU Yang. Effects of CYP2C19 gene polymorphism on the clinical prognosis of clopidogrel in elderly patients with acute cerebral infarction [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(9): 1014-1020.
[6]	PENG Jing, LIU Jun, XU Huifang, LI Yueran, JIANG Jia, WANG Sheng, ZHOU Dexi, ZHU Yanhong, YANG Kui, LUAN Jiajie. Correlation study between cytochrome P4502C19 gene polymorphism or metabolic type and ADP induced-platelet aggregation inhibition and clopidogrel resistance [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(7): 746-751.
[7]	YANG Rui, LIU Hui, CHEN Zeheng, QI Tingting，ZHANG Zanling, QU Qiang. Clinical pharmacists use CYP2C19 genotyping test to guide individual medication therapy of Clopidogrel and to evaluate the efficacy of treatment [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(8): 938-943.
[8]	CHEN Miao, ZHANG Xinjin, MENG Hongli, YANG Bei, SONG Lijuan, ZOU Chuannan, GUAN Yingxia. Therapeutic effect of bisoprolol combined with salvianolate on patients with coronary heart disease after PCI [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(4): 451-457.
[9]	WANG Ente, ZHANG Xiaodan, ZHOU Shuang, ZHAO Xia, ZHOU Ying, CUI Yimin. Effects of genetic polymorphisms on metabolic kinetics, pharmacodynamics and adverse reactions of amitriptyline [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(2): 235-240.
[10]	WEI Yuqiang. Protective effects of liraglutide on myocardium of AMI patients with the treatment of PCI [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(2): 184-188.
[11]	WANG Ying-ying, CHENG Guang-hua, PU Zhi-chen, GE Jun-liang, XIE Yan, CHEN Xiao-lei. Association between CYP2D6^10/CYP2C19^2 genotype polymorphism and survival of breast cancer patients receiving tamoxifen treatment [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2015, 20(5): 552-556.
[12]	CHEN Wang, WEN Chun-jie, FU Li-juan. Preliminary study of the CYP2C19 genotype in the application of Chinese herbal medicine metabolism screening [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(9): 1016-1020.
[13]	GAO Ru-ya ZHANG Ya-tong, CAO Guo-ying. Situation and suggestion on the pharmacotherapy before and after the percutaneous coronary intervention in Beijing hospital [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(10): 1110-1115.
[14]	LI Yun, HE Fang, ZENG Cai-wen, LIU Lin-lin, XIA Chun-hua. Effect of CYP2C9, CYP2C19, CYP3A4 polymorphism on metabolism of sulfonyluea antidiabetic drugs [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(5): 582-587.
[15]	CHEN Wang, YU Jing, QU Qiang, ZHANG Wei, LI Zhi, WU Lan-xiang, WEN Chun-jie, ZHOU Hong-hao. Construction of human CYP2C19 gene polymorphism eukaryotic expression vector and establishment of stably transfected HepG2 cell line expressing human CYP2C19 [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(3): 263-268.